Bailard’s ADMA Biologics ADMA Stock Holding History

Bailard’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-24,400	Closed	-$110K	–	733
2023 Q4	$110K	Buy	+24,400	New	+$90.3K	﹤0.01%	685
2023 Q3	–	Sell	-27,030	Closed	-$99.7K	–	697
2023 Q2	$99.7K	Buy	+27,030	New	+$100K	﹤0.01%	667

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bailard's ADMA Position: Q1 2024 in Review

Bailard sold out of ADMA Biologics (ADMA) in Q1 2024, closing a stake of 24,400 shares — an estimated $110K sold.

Bailard first reported a position in ADMA in Q2 2023 and held it in 2 quarters. The position peaked at $110K in Q4 2023. 214 funds tracked by Wall St. Rank hold ADMA as of Q1 2024.

Bailard reported no remaining ADMA Biologics position as of Q1 2024 after selling out during the quarter.
Bailard sold 24,400 ADMA Biologics shares in Q1 2024, an estimated $110K.
Bailard first reported a position in ADMA Biologics in Q2 2023 and held it in 2 quarters.
Bailard's ADMA Biologics position peaked at $110K in Q4 2023.
214 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2024.

Based on Bailard's 13F filing for Q1 2024, filed 8 May 2024.